LGC acquires Axolabs and invests in GMP manufacturing capacity for therapeutic nucleic acids

News (ZH) - Moves strengthen existing analytical and bioanalytical drug development service offering

LGC acquires Maine Standards Company, the leading provider of calibration verification materials for clinical laboratories in the US

News (ZH) - Acquisition bolsters growing portfolio of reference materials and PT schemes for the clinical market

LGC acquires Thistle QA, expands clinical PT offering

News (ZH) - Delighted to add Thistle to our leading global PT operations

Supporting new-born screening: LGC and NHS England Knowledge Transfer Partnership

News (ZH) - The UK National Measurement Laboratory at LGC are working in collaboration with Dr Rachel Carling, Consultant Clinical Scientist, Director of Service and Clinical Lead, Viapath, Guys & St Thomas' NHS Foundation Trust, one of the first recipients of the NHS Chief Scientific Officer's Knowledge Transfer Partnerships (KTP).

LGC acquires Seracare Life Sciences, strengthening its position in clinical quality control tools

News (ZH) - Strengthens LGC’s position across the spectrum of clinical quality control tools market

LGC helps NHS England launch a Knowledge Transfer Partnership for clinical leaders in healthcare science

News (ZH) - Making scientific innovation an intrinsic part of delivering a world-class NHS

The Full Authority Companion Diagnostic

博客 - Companion diagnostics are commonly qualitative yes/no tests that usually indicate whether or not a patient would have been included in the phase III trial that led to the approval of the companion diagnostic

Newly published multi-laboratory study provides utility and validation of the use of ctDNA reference standards

博客 - The study, “Multi-laboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements,” was published in The Journal of Molecular Diagnostics

LGC expands SARS-CoV-2 serology offering with 11-member positive-patient Performance Panel

News (ZH) - Panel demonstrates a range of SARS-CoV-2 antibody reactivity